Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure
Bibliographic record
Abstract
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disease that may require long-term disease management. The oral, once-daily Janus kinase 1–selective inhibitor abrocitinib has demonstrated efficacy through 112 weeks in patients with moderate-to-severe AD. Previous integrated safety analyses assessed adverse events of special interest (AESIs) by age and smoking status in 3802 patients (>5200 patient years [PY]; 4 years of abrocitinib exposure) and by age and cardiovascular (CV) risk factors in 3848 patients (>7000 PY; 4.5 years exposure). This study evaluated safety events stratified by age and smoking status using data from patients with ≥6.5 years of abrocitinib exposure. Procedure/study: Analysis included patients from 8 clinical trials (phase 2b [NCT02780167], JADE MONO-1 [NCT03349060], MONO-2 [NCT03575871], REGIMEN [NCT03627767], COMPARE [NCT03720470], TEEN [NCT03796676], MOA [NCT03915496], and DARE [NCT04345367]) and 1 long-term extension trial (JADE EXTEND [NCT03422822]; data cutoff: Dec 31, 2024). Incidence rates (IRs; number of patients with events/100 PY) of AESIs were assessed by age (<18; 18 to <40; 40 to <50; 50 to <65; and ≥65 years) and smoking status (never; current/former smoker). Results: Of 3850 patients in the pooled safety population (9655.4 PY exposure), 3052 received the same abrocitinib dose (consistent-dose cohort) and 798 patients comprised the variable-dose cohort. IRs in the consistent-dose cohort were numerically higher in older vs younger patients for major adverse CV events (MACEs; <18 years: 0.07 [0.00-0.42]; 18 to <40 y: 0.14 [0.04-0.32]; 40 to <50 y: 0.09 [0.00-0.51]; 50 to <65 y: 0.79 [0.32-1.63]; and ≥65 y: 2.03 [0.74-4.41]) and death (<18 years: 0.00 [95% CI, 0.00-0.28]; 18 to <40 y: 0.05 [0.01-0.20]; 40 to <50 y: 0.09 [0.00-0.51]; 50 to <65 y: 0.34 [0.07-0.99]; and ≥65 years 2.02 [0.74-4.40]). Similar trends were observed for other AESIs, including serious infections, herpes zoster, malignancies (excluding nonmelanoma skin cancer [NMSC]), NMSC, and venous thromboembolism (VTE). IRs for serious infections, malignancies (excluding NMSC), NMSC, MACE, VTE, and death were numerically higher in current/former smokers vs never smokers; herpes zoster IRs were comparable between smoking groups. Data from the variable-dose cohort generally showed similar trends. Conclusion: These long-term follow-up abrocitinib safety data in patients with >9600 PY of exposure are consistent with previously reported risk profiles. IRs tended to be higher in older patients and current/former smokers. Funding/Disclosures: This study was funded by Pfizer.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.003 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".